REGENXBIO announced positive 3-year results from its Phase II ALTITUDE trial of surabgene lomparvovec (sura-vec) for non-proliferative diabetic retinopathy (NPDR). A single in-office gene therapy dose led to over 60% of participants achieving more than a 2-step improvement on the Diabetic Retinopathy Severity Scale without additional treatments or vision-threatening events. No intraocular inflammation or new safety concerns were observed with short-term steroid use. These durable results highlight sura-vec's potential as a one-time treatment to reduce disease progression and the burden of repeated injections, with further trials ongoing.
The Health sector on Pluang saw 40 out of 100 US stocks rise while 60 fell, providing context for REGENXBIO's positive three-year durability data for surabgene lomparvovec in diabetic retinopathy. For readers following health stocks, here is Pluang's market snapshot as of Sep 25, 2026 05:51 WIB: NUWE traded at USD 0.80 with a 1-day change of -5.77% and a typical hold time of 23 days; DGX was priced at USD 232.90, down 5.51% over one day with a 55-day hold time; OSCR closed at USD 28.89, down 5.37%, with a 14-day hold time and nearly balanced buy/sell order activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Tanya Hart, Senior Executive Vice President and Chief Human Resources Officer at First Horizon, has been honored as the 2026 Distinguished Alumnus of the Year by Leadership Memphis. This award recognizes her significant leadership and community impac...
Chainlink's price jumped 5.72% to $12.96 following Infosys' announcement that it will standardize the Chainlink stack in its banking and payments software. Infosys manages systems covering 1.7 billion customer accounts, but no specific banks or timel...
Bitcoin has produced its fifth historic bullish signal, marked by a short-term holder cost basis crossing above that of active long-term holders, excluding dormant coins inactive for over seven years. This signal, identified by Cryptoquant analyst Da...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
